Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making
British Journal of Radiology · 23.01.2024 · 97 (1153) · 113-119
DOI: 10.1093/bjr/tqad027 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 12.12.2023. Verfasst von Ishwariya Rajendran und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge CB2 0QQ, United Kingdom. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
MRI is now established for initial prostate cancer diagnosis; however, there is no standardized pathway to avoid unnecessary biopsy in low-risk patients. Our study aimed to test previously proposed MRI-focussed and risk-adapted biopsy decision models on a real-world dataset.
Methods
Single-centre retrospective study performed on 2055 biopsy naïve patients undergoing MRI. Diagnostic pathways included “biopsy all”, “MRI-focussed” and two risk-based MRI-directed pathways. Risk thresholds were based on prostate-specific antigen (PSA) density as low (<0.10 ng mL−2), intermediate (0.10-0.15 ng mL−2), high (0.15-0.20 ng mL−2), or very high-risk (>0.20 ng mL−2). The outcome measures included rates of biopsy avoidance, detection of clinically significant prostate cancer (csPCa), missed csPCa, and overdiagnosis of insignificant prostate cancer (iPCa).
Results
Overall cancer rate was 39.9% (819/2055), with csPCa (Grade-Group ≥2) detection of 30.3% (623/2055). In men with a negative MRI (Prostate Imaging-Reporting and Data System, PI-RADS 1-2), the risk of cancer was 1.2%, 2.6%, 9.0%, and 12.9% in the low, intermediate, high, and very high groups, respectively; for PI-RADS score 3 lesions, the rates were 10.5%, 14.3%, 25.0%, and 33.3%, respectively. MRI-guided pathway and risk-based pathway with a low threshold missed only 1.6% csPCa with a biopsy-avoidance rate of 54.4%, and the risk-based pathway with a higher threshold avoided 62.9% (1292/2055) of biopsies with 2.9% (61/2055) missed csPCa detection. Decision curve analysis found that the “risk-based low threshold” pathway has the highest net benefit for probability thresholds between 3.6% and 13.9%.
Conclusion
Combined MRI and PSA-density risk-based pathways can be a helpful decision-making tool enabling high csPCa detection rates with the benefit of biopsy avoidance and reduced iPCa detection. Advances in knowledge This real-world dataset from a large UK-based cohort confirms that combining MRI scoring with PSA density for risk stratification enables safe biopsy avoidance and limits the over-diagnosis of insignificant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge CB2 0QQ, United Kingdom.
- Department of Radiology, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
- School of Medicine, Addenbrooke's Hospital, Cambridge CB2 0SP, United Kingdom.
Zitieren
APA
Rajendran, I., Lee, K. L., Thavaraja, L., & Barrett, T. (2024). Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making. British Journal of Radiology, 97(1153), 113-119. https://doi.org/10.1093/bjr/tqad027
Vancouver
Rajendran I, Lee KL, Thavaraja L, Barrett T. Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making. British Journal of Radiology. 2024;97(1153):113-119. doi:10.1093/bjr/tqad027
BibTeX
@article{Rajendran2024,
author = {Rajendran, Ishwariya and Lee, Kang-Lung and Thavaraja, Liness and Barrett, Tristan},
title = {Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making},
journal = {British Journal of Radiology},
year = {2024},
volume = {97},
number = {1153},
pages = {113--119},
doi = {10.1093/bjr/tqad027}
}
EUVIMED